-
公开(公告)号：US20160137595A1
公开(公告)日：2016-05-19
申请号：US14897668
申请日：2014-07-01
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Jay A. Markwalder , Steven P. Seitz , James Aaron Balog , Audris Huang , Sunil Kumar Mandal , David K. William , Amy C. Hart , Jennifer Inghrim
IPC: C07C275/42 , C07D213/79 , C07D257/04 , C07C311/51 , C07C311/09 , C07D307/79 , A61K45/06 , A61K31/196 , A61K31/4418 , A61K31/444 , A61K31/41 , A61K31/18 , A61K31/343 , A61K31/277 , C07D213/75
CPC classification number: C07C275/42 , A61K31/18 , A61K31/196 , A61K31/277 , A61K31/343 , A61K31/41 , A61K31/4418 , A61K31/444 , A61K45/06 , C07C311/09 , C07C311/51 , C07C2601/02 , C07C2601/14 , C07C2602/08 , C07C2602/10 , C07D213/75 , C07D213/79 , C07D257/04 , C07D307/79 , C07D307/86 , C07D401/04
Abstract: There are disclosed compounds of formula (I) that modulate or inhibit the enzymatic activity of indoleamine 2,3-di-oxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
Abstract translation: 公开了调节或抑制吲哚胺2,3-二加氧酶（IDO）的酶活性的式（I）化合物，含有所述化合物的药物组合物和治疗增殖性疾病如癌症，病毒感染和/或 使用本发明化合物的炎症性疾病。
-
公开(公告)号：US20160096847A1
公开(公告)日：2016-04-07
申请号：US14968259
申请日：2015-12-14
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： James Aaron Balog , Audris Huang
IPC: C07D498/04
CPC classification number: C07D498/04 , C07D409/04 , C07D409/14 , C07D413/04 , C07D413/06 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D495/04 , C07D519/00
Abstract: Disclosed are azaindazole compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein: X is O and Y is N; or X is S and Y is CH; Z is CR2 or N; Q is a heteroaryl; and R1 is defined herein. Also disclosed are methods of using such compounds in the treatment of at least one CYP 17 associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.
Abstract translation: 公开了式（I）的氮杂吲唑化合物或其药学上可接受的盐，其中：X为O且Y为N; 或X为S，Y为CH; Z是CR2或N; Q是杂芳基; 并且R1在本文中定义。 还公开了使用这些化合物治疗至少一种CYP17相关病症例如癌症的方法和包含这些化合物的药物组合物。
-
公开(公告)号：US10399933B2
公开(公告)日：2019-09-03
申请号：US15564153
申请日：2016-04-01
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： James Aaron Balog , Weiwei Guo , Audris Huang , Jay A. Markwalder , Weifang Shan , David K. Williams , Susheel Jethanand Nara , Saumya Roy
IPC: C07D309/14 , C07C275/40 , C07D211/10 , A61K31/17 , A61K31/196 , A61K31/277 , A61K31/351 , A61K31/382 , A61K31/397 , A61K31/428 , A61K31/437 , A61K31/445 , A61K31/501 , A61K31/505 , A61K31/506 , A61K31/519 , A61K31/5375 , A61K31/5377 , A61K31/538 , A61K39/395 , C07C229/42 , C07C255/58 , C07D205/04 , C07D211/14 , C07D239/47 , C07D265/36 , C07D277/64 , C07D295/155 , C07D309/04 , C07D335/02 , C07D401/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12 , C07D417/12 , C07D471/04 , C07D487/04 , C07D407/12 , C07D487/08 , C07D265/30 , C07D207/08 , C07D211/08 , C07D307/22 , C07C255/57 , C07C235/38 , C07C235/56 , C07C233/81 , C07C275/42 , C07D207/12 , C07D239/34 , C07D317/46 , C07D413/14 , C07D471/08 , C07C275/30 , A61K45/06
Abstract: There are disclosed compounds of formula (I) that modulate or inhibit the enzymatic activity of indoleamine-2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
-
公开(公告)号：US10399932B2
公开(公告)日：2019-09-03
申请号：US15564146
申请日：2016-04-01
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： James Aaron Balog , Emily Charlotte Cherney , Jay A. Markwalder , Steven P. Seitz , Weifang Shan , David K. Williams , Audris Huang , Susheel Jethanand Nara , Saumya Roy , Soodamani Thangavel , Ramesh Kumar Sistla , Srinivas Cheruku , Srinivasan Thangathirupathy , Yadagiri Kanyaboina , Nagalakshmi Pulicharla
IPC: C07D309/14 , C07D405/12 , C07D413/12 , C07D335/02 , C07D211/10 , C07D265/30 , C07D409/12 , C07C275/40 , A61K31/17 , A61K31/196 , A61K31/277 , A61K31/351 , A61K31/382 , A61K31/397 , A61K31/428 , A61K31/437 , A61K31/445 , A61K31/501 , A61K31/505 , A61K31/506 , A61K31/519 , A61K31/5375 , A61K31/5377 , A61K31/538 , A61K39/395 , C07C229/42 , C07C255/58 , C07D205/04 , C07D211/14 , C07D239/47 , C07D265/36 , C07D277/64 , C07D295/155 , C07D309/04 , C07D401/12 , C07D405/14 , C07D417/12 , C07D471/04 , C07D487/04 , C07D407/12 , C07D487/08 , C07D207/08 , C07D211/08 , C07D307/22 , C07C255/57 , C07C235/38 , C07C235/56 , C07C233/81 , C07C275/42 , C07D207/12 , C07D239/34 , C07D317/46 , C07D413/14 , C07D471/08 , C07C275/30 , A61K45/06
Abstract: There are disclosed compounds of formula (I) that modulate or inhibit the enzymatic activity of indoleamine-2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
-
公开(公告)号：US09758492B2
公开(公告)日：2017-09-12
申请号：US14914184
申请日：2014-08-26
Applicant: Bristol-Myers Squibb Company
Inventor： Jay A. Markwalder , Steven P. Seitz , James Aaron Balog , Audris Huang , Sunil Kumar Mandal , Shefali Srivastava , David K. Williams , Libing Chen
IPC: C07D257/04 , A61K31/17 , A61K31/18 , A61K31/381 , A61K31/41 , A61K31/422 , A61K31/427 , A61K31/4439 , A61K31/451 , A61K31/4709 , A61K31/497 , A61K31/50 , A61K31/506 , A61K31/5375 , A61K45/06 , C07D211/14 , C07D237/20 , C07D333/38 , C07D401/10 , C07D407/12 , C07D417/12 , C07D403/12 , C07D309/14 , C07D215/06 , C07D231/12 , C07D333/10 , C07D401/12 , C07D409/12 , C07D411/12 , C07D413/12 , C07D277/22 , C07C275/42 , C07C311/05 , C07C311/09 , C07C317/44 , C07B59/00
CPC classification number: C07D257/04 , A61K31/17 , A61K31/18 , A61K31/381 , A61K31/41 , A61K31/422 , A61K31/427 , A61K31/4439 , A61K31/451 , A61K31/4709 , A61K31/497 , A61K31/50 , A61K31/506 , A61K31/5375 , A61K45/06 , C07B59/002 , C07C275/42 , C07C311/05 , C07C311/09 , C07C317/44 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2601/16 , C07C2601/18 , C07D211/14 , C07D215/06 , C07D231/12 , C07D237/20 , C07D277/22 , C07D309/14 , C07D333/10 , C07D333/38 , C07D401/10 , C07D401/12 , C07D403/12 , C07D407/12 , C07D409/12 , C07D411/12 , C07D413/12 , C07D417/12
Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or autoimmune diseases utilizing the compounds of the invention.
-
Patent Agency Ranking
公开(公告)号：US20160200674A1
公开(公告)日：2016-07-14
申请号：US14914184
申请日：2014-08-26
Applicant: Bristol-Myers Squibb Company
Inventor： Jay A. Markwalder , Steven P. Seitz , James Aaron Balog , Audris Huang , Sunil Kumar Mandal , Shefali Srivastava , David K. Williams , Libing Chen
IPC: C07C275/42 , A61K31/41 , A61K45/06 , C07C311/09 , A61K31/18 , A61K31/17 , C07D417/12 , A61K31/427 , C07D333/38 , A61K31/381 , C07D401/10 , A61K31/4439 , C07D407/12 , C07D211/14 , A61K31/451 , C07D403/12 , A61K31/506 , C07D413/12 , A61K31/422 , A61K31/497 , A61K31/4709 , C07D237/20 , A61K31/50 , A61K31/5375 , C07D257/04
CPC classification number: C07D257/04 , A61K31/17 , A61K31/18 , A61K31/381 , A61K31/41 , A61K31/422 , A61K31/427 , A61K31/4439 , A61K31/451 , A61K31/4709 , A61K31/497 , A61K31/50 , A61K31/506 , A61K31/5375 , A61K45/06 , C07B59/002 , C07C275/42 , C07C311/05 , C07C311/09 , C07C317/44 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2601/16 , C07C2601/18 , C07D211/14 , C07D215/06 , C07D231/12 , C07D237/20 , C07D277/22 , C07D309/14 , C07D333/10 , C07D333/38 , C07D401/10 , C07D401/12 , C07D403/12 , C07D407/12 , C07D409/12 , C07D411/12 , C07D413/12 , C07D417/12
Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or autoimmune diseases utilizing the compounds of the invention.
Abstract translation: 公开了调节或抑制吲哚胺2,3-双加氧酶（IDO）的酶活性的化合物，含有所述化合物的药物组合物和治疗增殖性疾病的方法，例如癌症，病毒感染和/或自身免疫疾病，其利用 发明。
-
公开(公告)号：US20160143870A1
公开(公告)日：2016-05-26
申请号：US14903091
申请日：2014-07-10
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Jay A Markwalder , James Aaron Balog , Audris Huang , Steven P Seitz
IPC: A61K31/196 , C07C233/55 , C07D257/04 , A61K31/41 , C07D405/12 , C07D401/10 , A61K31/454 , C07D401/12 , A61K31/4439 , C07D417/12 , A61K31/427 , C07D413/12 , A61K31/422 , A61K31/5377 , C07D403/10 , A61K31/4155 , C07D487/08 , A61N5/10 , A61K45/06
CPC classification number: A61K31/196 , A61K31/41 , A61K31/4155 , A61K31/422 , A61K31/427 , A61K31/4439 , A61K31/454 , A61K31/5377 , A61K45/06 , A61N5/10 , C07C233/55 , C07C255/57 , C07C2601/14 , C07D257/04 , C07D261/08 , C07D401/10 , C07D401/12 , C07D403/10 , C07D405/12 , C07D409/12 , C07D413/12 , C07D417/12 , C07D487/08 , Y02A50/411 , Y02A50/414
Abstract: There are disclosed compounds of Formula (I) that modulate or inhibit the enzymatic activity of indoleamine 2,3-di-oxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or autoimmune diseases utilizing the compounds of the invention.
Abstract translation: 公开了调节或抑制吲哚胺2,3-二加氧酶（IDO）的酶活性的式（I）化合物，含有所述化合物的药物组合物和治疗增殖性疾病如癌症，病毒感染和/或 使用本发明化合物的自身免疫性疾病。
-
公开(公告)号：US20160060237A1
公开(公告)日：2016-03-03
申请号：US14775976
申请日：2014-03-12
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： James Aaron Balog , Audris Huang , Bin Chen , Libing Chen , Weifang Shan
IPC: C07D305/06 , A61K31/196 , A61K31/337 , C07D261/14 , A61K31/42 , A61K45/06 , A61K31/41 , C07D241/42 , A61K31/498 , C07D239/42 , A61K31/505 , C07C275/42 , C07D255/02
CPC classification number: C07D305/06 , A61K31/196 , A61K31/337 , A61K31/41 , A61K31/42 , A61K31/498 , A61K31/505 , A61K45/06 , C07C275/42 , C07C2101/14 , C07C2601/14 , C07D239/42 , C07D241/42 , C07D255/02 , C07D261/14
Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or autoimmune diseases utilizing the compounds of the invention. Formula (I).
Abstract translation: 公开了调节或抑制吲哚胺2,3-双加氧酶（IDO）的酶活性的化合物，含有所述化合物的药物组合物和治疗增殖性疾病的方法，例如癌症，病毒感染和/或自身免疫疾病，其利用 发明。 式（I）。
-
公开(公告)号：US20240376082A1
公开(公告)日：2024-11-14
申请号：US18740857
申请日：2024-06-25
Applicant: Bristol-Myers Squibb Company
Inventor： Yan Chen , Godwin Kwame Kumi , Audris Huang , Satheesh Kesavan Nair , Bharat Dinkar Shimpukade , Suresh Babu Vishwa Krishna Penmetsa , James Aaron Balog
IPC: C07D401/14 , A61P35/00
Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein R1, R2, R4, R6, m, and n are defined herein. Also disclosed are methods of using such compounds to inhibit Helios protein, and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
-
公开(公告)号：US20230303527A1
公开(公告)日：2023-09-28
申请号：US18331348
申请日：2023-06-08
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Yan Chen , Godwin Kwame Kumi , Audris Huang , Satheesh Kesavan Nair , Bharat Dinkar Shimpukade , Suresh Babu Vishwa Krishna Penmetsa , James Aaron Balog
IPC: C07D401/14 , A61P35/00
CPC classification number: C07D401/14 , A61P35/00
Abstract: Disclosed are compounds of Formula (I):
or a salt thereof, wherein R1, R2, R4, R6, m, and n are defined herein. Also disclosed are methods of using such compounds to inhibit Helios protein, and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
-
-
-
-
-
-
-
-
-
Search Results
35
records
(took 0.077 seconds)
